Know Cancer

forgot password

Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer

Phase 2
18 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer

Inclusion Criteria:

1. Female patients with histologically confirmed diagnosis of primary unilateral
invasive early breast cancer with longest tumor size in breast ≥ 2cm, or < 2 cm with
axillary involvement. In case of a multifocal tumor (tumor foci located in the same
quadrant) the largest lesion must be ≥ 2cm (unless axillary involvement) and is
designated as the "target" lesion for all subsequent tumor evaluations.

2. The breast tumors must be ER positive: more than 1% of stained tumor cells by IHC,
and HER2 negative: 0, or 1+ score by IHC, or 2+ with FISH/CISH negative for HER2
amplification (defined as a ratio of HER-2/neu copies to chromosome 17 centromere
(CEP17) signals <1.8), according to the local laboratory).

3. Are clear candidates to receive chemotherapy by the investigator criteria.

4. Are at least 18 years of age.

5. Have at least one unidimensionally measurable lesion by RECIST [65] version 1.1,
measured by mammogram.

6. Have adequate performance status: Eastern Cooperative Oncology Group (ECOG) <2

7. Have adequate renal and liver function and bone marrow reserve as follows:

- Bone marrow: ANC > or = 1.500/mm3 (1.5 x 109/L); platelet count > or =
100.000/mm3 (100.0 x 109/L); and hemoglobin > or = 9 g/dL.

- Hepatic: bilirubin < or = 1.5 times the upper limit of normal (x ULN); alkaline
phosphatase (ALP), aspartate transaminase (AST), and alanine transaminase (ALT)
< or = 2.5 * ULN and Albumin ≥ 2.5 g/dL.

- Renal: serum creatinine < 1.5 x ULN.

8. Exhibit patient compliance and geographic proximity that allow for adequate follow-up

9. Entry informed consent form signed by the patient.

Exclusion Criteria:

1. Inflammatory breast cancer (T4d) and supraclavicular lymph nodes (N3)

2. Synchronous contralateral or multicentric breast cancer.

3. Clinical or radiologic evidence of metastatic disease. Chest examination by x-ray or
CT-scan, abdominal examination by CT-scan, bone examination by bone scan as well as
other radiological methods in case of suspicion must be performed before enrollment
in order to rule out metastasis.

4. Second primary malignancy, except adequately treated carcinoma in situ of the cervix,
stage I colon cancer, non-invasive melanoma, basal or squamous cell carcinomas of the
skin, ipsilateral ductal carcinoma in-situ (DCIS) of the breast and lobular carcinoma
in-situ (LCIS) of the breast; unless that prior malignancy was diagnosed and
definitively treated more than 5 years ago with no subsequent evidence of recurrence.

5. Prior or concurrent anti-cancer therapy for current disease (hormone therapy,
chemotherapy, radiotherapy, immunotherapy, biological therapy other than the trial

6. Concurrent treatment with any hormonal treatment either for osteoporosis or as
replacement therapy.

7. Patients with known hypersensitivity to nab-paclitaxel or any of its components.

8. Previous neuropathy grade >1 according to the NCI-CTCAE vs 4.03 criteria

9. Have received treatment within the last 4 weeks with a drug that has not received
regulatory approval for any indication at the time of study entry.

10. Have any serious concomitant systemic disorder incompatible with the study (at the
discretion of investigator).

11. Patient is pregnant or breast feeding or planning to become pregnant within the six
months after the end of treatment. Women with child-bearing potential must be
performed a pregnancy serum or urine testing within 7 days prior to study entry
according to institutional standards and should use an adequate non-hormonal
contraceptive method (intra-uterine contraceptive device, barrier method of
contraception in conjunction with spermicidal jelly or surgically sterilized) during
treatment with study drugs and within the six months after the end of treatment.

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The residual cancer burden grade III (RCB-III).

Outcome Description:

The RCB-III will be reported, including a 95% confidence interval. The estimate of the RCB-III will be calculated as follows: Overall Response Rate = Number of patients with RCB-III / ITT population

Outcome Time Frame:

After the last enrolled patient has recieved surgery (Around 29 months since the beginning of the study)

Safety Issue:


Principal Investigator

Miguel Martín, PhD., MD.

Investigator Role:

Study Director

Investigator Affiliation:

Hospital General Universitario Gregorio Marañón


Spain: Spanish Agency of Medicines

Study ID:




Start Date:

June 2013

Completion Date:

August 2019

Related Keywords:

  • Breast Cancer
  • Neoadjuvant nab-paclitaxel luminal breast cancer
  • Breast Neoplasms